Skip to main content
Explore URMC
menu

Study of infusion treatment, axicabtagene ciloleucel, for patients with Indolent Non-Hodgkin Lymphoma

Research Question:
For patients who have relapsed from or have refractory Indolent Non-Hodgkin Lymphoma, what is the disease response and safety when infused with the study treatment, axicabtagene ciloleucel?

Basic Study Information

Purpose:
Axicabtagene ciloleucel is an experimental product made from the subject's own white blood cells which are genetically modified and grown to fight cancer. Patients will be infused with axicabtagene ciloleucel to see if their disease responds and if this product is safe. This study will enroll approximately 160 adult subjects who have relapsed or refractory Indolent Non-Hodgkin Lymphoma.

Location: University of Rochester Medical Center
Study Reference #: ILYM-17047

Lead Researcher (Principal Investigator)

Lead Researcher: Carla Casulo

Study Contact Information

Study Coordinator: Yelena Lerman
Phone: (585) 276-8333
Email: ylerman@URMC.Rochester.edu

Additional Study Details

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search